Sugi Predict

Sugi Predict / Compounds / SCHEMBL760442

SCHEMBL760442

SCHEMBL760442

Ic1cccnc1OCC1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 3/20 0.45
▸ HTR4 Q13639 3/20 0.45
▸ HTR2A P28223 2/20 0.45
▸ HTR7 P34969 2/20 0.45
▸ HTR1A P08908 1/20 0.45
▸ ALOX5AP P20292 2/20 0.41
▸ FEN1 P39748 2/20 0.41
▸ HTR2B P41595 2/20 0.40
▸ HTR3A P46098 2/20 0.40
▸ HTR5A P47898 1/20 0.40
▸ FFAR4 Q5NUL3 2/20 0.39
▸ PDE5A O76074 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ GPBAR1 Q8TDU6 1/20 0.37
▸ ACHE P22303 2/20 0.37
▸ CDK1 P06493 2/20 0.36
▸ CCNB1 P14635 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16334718 0.93 HTR2C (0.44) HTR2CHTR4HTR2AHTR7HTR1A
SCHEMBL16334921 0.83 GRM4 (0.47) —
SCHEMBL13257866 0.79 SSTR4 (0.43) HTR2CHTR4HTR1AALOX5APFEN1
SCHEMBL16175485 0.79 SSTR4 (0.41) HTR2CHTR4HTR2AHTR7HTR1A
SCHEMBL19171957 0.79 ALOX5AP (0.46) ALOX5APFEN1FFAR4PDE5APDE4A
SCHEMBL25347064 0.79 ALOX5AP (0.41) HTR2CHTR4ALOX5APFEN1HTR2B
SCHEMBL20652941 0.77 MKNK2 (0.41) HTR2CHTR4HTR2AHTR7HTR1A
SCHEMBL20652975 0.77 MKNK2 (0.41) HTR2CHTR4HTR2AHTR7HTR1A
SCHEMBL20652981 0.77 MKNK2 (0.41) HTR2CHTR4HTR2AHTR7HTR1A
SCHEMBL16334496 0.77 POLB (0.46) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107567443-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-28 — — CN disclosed
CN-115925679-A Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-07 — — CN disclosed
EP-3239143-B1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEMICAL LTD (KR) 2023-03-22 — — EP disclosed
CN-110997675-B Novel substituted xanthine derivatives 勃林格殷格翰国际公司 2022-06-07 — — CN disclosed
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEM, LTD. (KR) 2022-05-05 — — US disclosed
US-11261186-B2 Biaryl derivative as GPR120 agonist LG CHEM. LTD. (KR) 2022-03-01 — — US disclosed
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
CN-105392777-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2020-09-22 — — CN disclosed
EP-3013796-B9 BIARYL DERIVATIVES AS GPR120 AGONISTS LG CHEMICAL LTD (KR) 2020-07-01 — — EP disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed
US-20170349594-A1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEM, LTD. (KR) 2017-12-07 — — US disclosed
EP-3239143-A2 BIARYL DERIVATIVE AS GPR120 AGONIST LG Chem, Ltd. (KR) 2017-11-01 — — EP disclosed
US-20160168096-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG LIFE SCIENCES LTD. (KR) 2016-06-16 — — US disclosed
EP-3013796-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG Life Sciences Ltd. (KR) 2016-05-04 — — EP disclosed
WO-2014209034-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG LIFE SCIENCES LTD. (KR) 2014-12-31 — — WO disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 — — US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 — — US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 HTR2C 3174/4885HTR4 4014/4885HTR2A 4030/4885
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST GPR119, GLP1R, GIPR HTR2C 1582/4885HTR4 2223/4885HTR2A 1214/4885
US-20160168096-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS GPR119, GLP1R, GIPR HTR2C 1842/4885HTR4 2117/4885HTR2A 1251/4885
US-20170349594-A1 BIARYL DERIVATIVE AS GPR120 AGONIST GPR119, GLP1R, GIPR HTR2C 1582/4885HTR4 2223/4885HTR2A 1214/4885
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPV1 HTR2C 437/4885HTR4 292/4885HTR2A 524/4885
US-11261186-B2 Biaryl derivative as GPR120 agonist GPR119, GPR88, FFAR1 HTR2C 818/4885HTR4 1273/4885HTR2A 643/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 HTR2C 3174/4885HTR4 4014/4885HTR2A 4030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.